The Society for Immunotherapy of Cancer (SITC) hosted Session 208d during the 39th Annual Meeting & Pre-Conference Programs on Saturday, November 9, 2024. Available here are the presentation slides and video from “Session 208d: CAR-T cells vs T-cell engaging bispecifics in Hematological Malignancies” as permitted by presenters. This session is co-organized by the Society for Immunotherapy of Cancer (SITC) and The Myeloid Network.
Natalie Grover, MD – University of North Carolina
Aurélien Marabelle, MD, PhD – Gustave Roussy, France
Join our session to explore the latest advancements in CAR-T cells and bispecific T-cell engagers for the treatment of hematological malignancies. Discover the unique advantages, challenges, and opportunities of these novel therapies in revolutionizing patient outcomes. Learn about the current innovation in cell therapy and drug design but also the specific adverse events of such constructs. Don't miss this opportunity to gain insights from leading experts in the field and to access the latest advances from selected SITC abstracts.
To view the entire program schedule (including presenter permission to post) please click here.
01:33:56